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RESEARCH ARTICLE
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Myeloid-derived suppressor cells (MDSCs) represent an innate immune
cell population comprised of immature myeloid cells and myeloid progenitors with
very potent immunosuppressive potential. MDSCs are reported to be abundant in
the lungs of active tuberculosis (TB) patients. We sought to perform an in-depth
study of MDSCs during latent TB infection (LTBI) and active TB (ATB) using the nonhuman primate (NHP) model of pulmonary TB. We found a higher proportion of
granulocytic, polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) in
the lungs of ATB animals compared to those with LTBI or naive control animals.
Active disease in the lung, but not LTBI, was furthermore associated with higher proliferation, expansion, and immunosuppressive capabilities of PMN-MDSCs, as shown
by enhanced expression of Ki67, indoleamine 2,3-dioxygenase (IDO1), interleukin-10
(IL-10), matrix metallopeptidase 9 (MMP-9), inducible nitric oxide synthase (iNOS), and
programmed death-ligand 1 (PD-L1). These immunosuppressive PMN-MDSCs speciﬁcally
localized to the lymphocytic cuff at the periphery of the granulomas in animals with
ATB. Conversely, these cells were scarcely distributed in interstitial lung tissue and the
inner core of granulomas. This spatial regulation suggests an important immunomodulatory role of PMN-MDSCs by restricting T cell access to the TB granuloma core and
can potentially explain dysfunctional anti-TB responses in active granuloma. Our results
raise the possibility that the presence of MDSCs can serve as a biomarker for ATB, while
their disappearance can indicate successful therapy. Furthermore, MDSCs may serve as
a potential target cell for adjunctive TB therapy.
IMPORTANCE Myeloid cells are immunocytes of innate origin that orchestrate the ﬁrst

response toward pathogens via immune surveillance (uptake and killing), antigen presentation, and initiation of adaptive immunity by T cell stimulation. However,
MDSCs are a subset of innate immunocytes that deviate to an immunoregulatory
phenotype. MDSCs possess strong immunosuppressive capabilities that are
induced in autoimmune, malignant neoplastic, and chronic inﬂammatory diseases.
Induction of MDSCs has been found in peripheral blood, bronchoalveolar lavage
(BAL) ﬂuid, and pleural effusions of active TB patients, but their precise localization in lung tissue and in TB granulomas remains unclear due to challenges associated with sampling lungs and granulomas from active TB patients. Nonhuman
primates (NHPs) are an important animal model with TB granulomas that closely
mimic those found in humans and can therefore be used for studies that are otherwise challenging with patient material. Herein, we study MDSC localization in
the lungs of NHPs exhibiting latent and active TB. Our ﬁndings reveal that MDSCs
localize and exert their immunosuppressive roles at the periphery rather than in
the core of TB granulomas.
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uberculosis (TB) was the deadliest infectious disease of humanity prior to the onset
of the COVID-19 pandemic. In the past year, COVID-19 became a global health priority, but with the availability of several efﬁcacious vaccines against COVID-19, TB is widely
expected to regain its place as the infectious disease leading to the greatest mortality
worldwide (1). The vast majority of individuals can control infection with Mycobacterium
tuberculosis, the causative organism of TB, by restricting the pathogen and associated
immune response to localized tissue environments called granulomas. This is believed to
be the basis of latency in M. tuberculosis infection (2, 3). Yet, in a number of cases, latent
TB infection (LTBI) either is not established or recrudescence can occur after the initial
establishment of latency. Having coevolved with its human host, M. tuberculosis has
developed multiple host immune evasion mechanisms during the course of its infection.
In fact, the development of active disease is chieﬂy driven by dysregulation of effective
immunity (4).
Classiﬁcation and characterization of MDSCs. M. tuberculosis primarily infects macrophages, and cells of myeloid origin mount the initial response to infection (5). Recent
studies have established myeloid-derived suppressor cells (MDSCs) as an innate
immune population comprised of immature myeloid cells and myeloid progenitors
with very potent immunosuppressive potential. MDSCs represent a unique population
of myeloid cells that deviate from their regular fate to differentiate into macrophages,
granulocytes, or dendritic cells (DCs) under physiological conditions like aging (6) or
pathological conditions like chronic inﬂammation (7–11) or cancer (12–15). They are
usually classiﬁed into monocytic MDSCs (M-MDSCs) or polymorphonuclear MDSCs
(PMN-MDSCs) based on their nuclear organization and expression of key surface receptors. In humans, both of these subsets express CD11b. M-MDSCs are mononuclear and
express CD14, while PMN-MDSCs exhibit a polymorphic nuclear organization with the
expression of CD15 and CD66b. Both the MDSC subsets express the general myeloid
marker CD33 in humans and lack lineage markers for lymphocytes and NK cells. While
the M-MDSC markers overlap with monocytes, M-MDSCs are distinguished from monocytes by their absence of HLA-DR expression. MDSCs develop from bone marrow hematopoietic precursors due to altered myelopoiesis induced by sustained inﬂammatory response, although their development from mature myeloid cell populations
cannot be ruled out yet.
In human blood, M-MDSCs are present in the same density fraction as monocytes,
but differ from the latter by the virtual absence of HLA-DR expression. They can accurately be characterized as lymphocyte lineage marker-negative cells with a CD11b1 or
CD331/HLA-DR2 CD141 CD152 phenotype. M-MDSCs display high CD33 expression
compared to PMN-MDSCs. Murine MDSCs express Gr1 and CD11b, along with variable
expression of Ly6C and Ly6G. The two major subsets are characterized as Gr-11 CD11b1
Ly6G2/lo Ly6Chi for M-MDSCs and CD11b1 Ly6G1 Ly6Clo/int for PMN-MDSCs (16). PMNMDSCs express other markers, including activation markers like CD62L, CD54/ICAM-1,
CD63, and CD274/PD-L1, chemokine receptors like CXCR2 and CXCR4, and functional
markers like arginase 1 (ARG1), lectin-like oxidized low-density lipoprotein (LDL) receptor1 (Lox-1), and indoleamine 2,3-dioxygenase (IDO1).
MDSCs—potent suppressors of immune functions. MDSCs have been well studied in neoplastic malignancies and conclusively shown to induce their immunosuppressive effects on antigen-speciﬁc T cells, spanning both the priming as well as
effector phases of tumor-inﬁltrating lymphocytes (TILs) (17). MDSCs also inhibit
effector responses like cytokine responses, proliferation, and lytic activities of TILs
(18). The loss of these functions is not due to exhaustion, as puriﬁcation and antigenic challenges post-in vitro culture have been reported to restore the effector
responses in TILs (18–21). Microscopic colocalization interrogations in primary
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FIG 1 MDSCs in peripheral blood correlate with disease severity in M. tuberculosis-infected RMs. Shown is a graphical representation of correlates
of TB disease in M. tuberculosis-infected macaques showing severity of disease in ATB (red) and LTBI (green). (A) Serum CRP level. (B) CXR score. (C)

(Continued on next page)
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human cancer tissues have established the MDSC-T cell immunological synapses to
reside within the intratumoral regions (22). The magnitude of suppressive effects of
MDSCs on TILs has a direct correlation with proximal localization and physical
engagement (22). Apart from cancer, transplantation, and inﬂammatory pathologies,
where these cells are extensively studied (12–15), MDSCs have been recently
reported to be abundant in the blood (7, 23, 24), pleural effusions (7), and bronchoalveolar lavage (BAL) ﬂuid (23) of active TB (ATB) patients. MDSCs could potently
impair adaptive immunity by killing DCs (25) or inhibiting T cell functions (7, 9, 10,
22, 25–35).
MDSC-driven T cell dysfunction spans inhibition of activation, proliferation, and/or
effector functions of both CD41 helper T cells and CD81 cytotoxic T cells by multiple
mechanisms. These include metabolite-driven suppression via IDO1, inducible nitric
oxide synthase (iNOS), etc., or initiation of an anti-inﬂammatory cytokine cascade
driven by interleukin-10 (IL-10), transforming growth factor b (TGF- b ), etc., or via direct
cell contact-dependent inhibition mediated by transfer of cytoplasmic material to T
cells from MDSCs (10, 25, 29–36). Myelopoiesis-promoting growth factors, such as
granulocyte colony-stimulating factor (G-CSF) (37, 38), macrophage CSF (M-CSF), and
granulocyte-macrophage CSF (GMCSF) (39), act together with inﬂammatory cytokines
to promote MDSC expansion and to prevent their differentiation into terminally differentiated DCs, macrophages, or granulocytes (39). MDSCs potently suppress the function of both CD4 and CD8 T cells (10, 22, 25–33, 35, 36). Adoptive transferred MDSCs
can induce antigen-speciﬁc CD8 T cell tolerance in mice (40). Compared with other tolerogenic myeloid cells (e.g., regulatory DCs or regulatory macrophages) (12–15),
MDSCs are unique in that they can be activated to suppress immunity by inﬂammatory
signals (7, 8, 11, 25, 30, 32). These include proinﬂammatory cytokines that are elevated
after surgery and Toll-like receptor ligands, making MDSCs potentially well suited for
targeting by adjunctive immunotherapeutics (11, 25, 30, 32, 34, 35, 41). MDSCs have
recently received attention as potential targets for anti-TB immunotherapy (11, 25, 30,
32, 34, 35, 41).
MDSCs in tuberculosis. Although there exist limited data on the role of MDSCs in
TB, several studies in murine models of TB, particularly C3HeB/FeJ, C57BL/6, 129S2,
NOS22/2, and RAG22/2mice have shown that MDSCs are generated during TB infection. The immunocompromised mice possessed higher frequencies of MDSCs compared to TB-resistant or wild-type mice, where these cells lead to suppression of T cell
proliferation and functions. With the course of TB progression, the accumulation of
MDSCs is accompanied by the loss of conventional neutrophils. Selective depletion of
MDSCs in C3HeB/FeJ mice has been shown to reduce bacillary burden and promote T
helper 1 (TH1) responses (42). The presence of a high number of MDSCs correlates
with increased surface expression of IL-4 receptor a (IL-4Ra), resulting in an inability to
control M. tuberculosis infection, thereby leading to profound TB progression and
lethality (9, 43).
In humans, the frequency and effect of MDSCs have been studied in the blood of
ATB and LTBI patients. Blood from ATB individuals was reported to possess signiﬁcantly
higher MDSC frequencies than blood from individuals with LTBI. Moreover, MDSCs iso-

FIG 1 Legend (Continued)
Bacterial burden at necropsy measured in lung (CFU/g of lung). (D) Lung involvement, quantiﬁed for every animal as the percentage of the lung
with histopathologic abnormalities, including granulomatous inﬂammation, necrosis, hemorrhage, and edema. (E to J) Comparison of neutrophils,
PMNs, and M-MDSCs in the three study groups: ATB (red), LTBI (green), and naive control (blue). (E and H) Percentage of neutrophils (PMNs) in BAL
ﬂuid (E) and blood (H). (F and I) Fractions of PMN-MDSCs gated as CD32 CD202 CD66abce1 CD142/int HLA-DR2 CD331 in BAL ﬂuid (F) and
peripheral blood (I) at necropsy. (G and J) Fraction of M-MDSCs gated as CD32 CD202 CD66abce2 CD141 HLA-DR2 in BAL ﬂuid (G) and blood (J).
(K) Multilabel immunoﬂuorescence tiled image of a TB granuloma from an M. tuberculosis-infected lung showing IDO1 expression in PMN-MDSCs
(marked by CD66abce and CD33). (B to D) Statistical signiﬁcance by two-tailed unpaired t test with no correction: *, P , 0.05; **, P , 0.01; ***, P ,
0.001; ****, P , 0.0001. (A and E to J) Statistical signiﬁcance by one-way ANOVA with Tukey’s multiple-testing correction: *, P , 0.05; **, P , 0.01;
***, P , 0.001; ****, P , 0.0001. Data represent mean 6 standard error of the mean (SEM). Naive mice (n = 6) are shown in blue, M. tuberculosis
CDC1551-infected LTBI mice (n = 6) are shown in green, and M. tuberculosis CDC1551-infected ATB mice (n = 6) are shown in red.
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FIG 2 MDSCs induced in TB localize to the lymphocytic cuff at the periphery of granuloma. Comparison of PMN-MDSCs in lungs of the three study
groups: ATB (red), LTBI (green), and naive control (blue). Shown are the stitched confocal images (4-by-4 ﬁelds at 10 magniﬁcation) of formalin-ﬁxed

(Continued on next page)
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lated from ATB patients were able to suppress T cell proliferations by up to 72% and
also subvert the mycobacterial containment (44). The ﬁndings that MDSCs provide a
niche for M. tuberculosis survival, which in turn results in immunity to TB, advocates
that MDSCs can serve as susceptible targets for host-directed therapies for TB prevention (45).
Characterization of MDSCs in NHP model of TB. Nonhuman primates (NHPs) are
an important animal model of TB (46) and, in particular, a model of M. tuberculosishost interaction within human-like granulomas, and as such are ideal for testing
anti-TB immunotherapeutics (47). MDSCs have been well characterized in mice and
humans (48–50); however, only limited information is available about these cells in
NHPs (39), particularly in the NHP TB model. Recently, Sui et al. demonstrated an
increase in MDSCs in TB-vaccinated rhesus macaques (RMs) and the ability of these
cells to suppress T cell responses in vitro (26). Due to variations in immunocyte phenotypes among humans and RMs, along with limited availability and repertoire of
cross-reactive antibodies, phenotypic approaches used for characterizing human
MDSCs cannot be directly employed for characterizing rhesus MDSCs. A major phenotypic difference among immune cells of humans and RMs is differential expression of CD56, which is a unique lineage-determining marker for human NK cells and
is also present on a subset of monocytes in RMs. Alternatively, CD8/NKG2A
expressed on NK cells in RMs can be used along with CD3 and CD20 to exclude
lymphoid cells in a gating strategy to identify rhesus MDSCs. CD14 expression can
be used to identify monocytes and M-MDSCs in both RMs and humans (51, 52).
Similarly, CD66abce can be used to characterize neutrophils and PMN-MDSCs in
both humans and RMs (51, 52). CD33 is a key marker used to identify human MDSCs,
with high expression on human M-MDSCs and intermediate expression on PMNMDSCs. However, only one antibody clone has been validated to recognize CD33 in
RMs (53). In RMs, immunosuppressive functions have been attributed to a monocyte
subpopulation lacking HLA-DR expression (51). The RM low-density neutrophil (LDN)
population comprises both CD332 and CD331 cells, of which only the CD331 subset
can exert immunosuppressive functions by inhibiting T cell responses and is thus
deﬁned as PMN-MDSCs (53).
We sought to conduct an in-depth characterization of MDSCs during latent TB
and ATB by using the NHP model of pulmonary TB at the site of infection. We ﬁrst
used high-parameter ﬂow cytometry to develop gating strategies to identify different types of MDSCs (PMN- versus M-MDSCs) in the lung compartment in M. tuberculosis-infected rhesus macaques (RMs). Next, we employed multicolor confocal imaging in lung sections to phenotype MDSCs and elucidate their spatial localization
with respect to TB granuloma in NHP lungs. Our aim was to deﬁne the spatial distribution of MDSCs in lung TB granulomas and gain better insight into their potential
role in driving the granulomatous architecture. Our study demonstrates that ATB is
characterized by a measurable increase in MDSC levels in both peripheral blood
and BAL ﬂuid, with signiﬁcant recruitment of these cells to the outer periphery of
the granulomas. Our results raise the possibility that MDSCs can serve as a promising biomarker for ATB, while their disappearance could correlate with successful
therapy (7–9, 11, 30, 33). Furthermore, they may serve as a potential target for adjunctive TB therapeutics (9, 11, 25, 30, 32, 35, 36, 41), helping to resolve the granu-

FIG 2 Legend (Continued)
and parafﬁn-embedded lung sections depicting control naive lung (A) and granuloma obtained from LTBI (B) and ATB RMs (C). Images from naive,
LTBI, and ATB lung depicting PMN-MDSCs stained with CD66abce (green), CD33 (red), IDO1 (magenta), and DAPI (blue) at 10 and 63 magniﬁcation
(D). Estimated fractions of PMNs (CD66abce1) (E), PMN-MDSCs (CD66abce1 CD331) (F), and IDO11 PMN-MDSCs (CD66abce1 CD331 IDO11) (G) are
shown in lung sections of ATB (red), LTBI (green), and naive (blue) macaques. (H) Images showing the distribution of PMN-MDSCs in various regions of
granuloma and active lung interstitium. (I to K) Graphs showing estimated fractions of PMNs (CD66abce1) (I), PMN-MDSCs (CD66abce1 CD331) (J), and
PMN-MDSCs (CD66abce1 CD331 IDO11) (K) in different regions of granuloma: the necrotic core (NC), intermediate myeloid layer (IM), lymphocytic cuff
(LC), active TB lung interstitium (ALI), and naive lung interstitium (NLI). Statistical signiﬁcance by one-way ANOVA with Tukey’s multiple-testing
correction: *, P , 0.05; **, P , 0.01; ***, P , 0.001; ****, P , 0.0001. Data represent mean 6 SEM (n = 4).
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FIG 3 Highly proliferative phenotype in MDSCs recruited to the lungs of RMs with ATB. Lung sections from ATB, LTBI, and naive groups were
stained for CD66abce, CD33, and Ki67. Shown are the stitched confocal images (4-by-4 ﬁelds at 10) of formalin-ﬁxed and parafﬁn-embedded lung

(Continued on next page)
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RESULTS
Gating strategy for MDSC characterization in RMs. For deﬁning MDSCs in RM for
this study, we used the gating strategy depicted in Fig. S1A in the supplemental material. Brieﬂy, M-MDSCs were gated as CD32 CD202 CD66abce2 CD141 HLA-DR2 and
PMN-MDSCs gated as CD32 CD202 CD66abce1 CD142/INT HLA-DR2 CD331. The comparative analysis of phenotypic differences among gated PMN-MDSCs and M-MDSCs is
depicted in Fig. S1B.
Distribution of MDSCs in ATB, LTBI, and naive RMs. To study the role of MDSCs
during ATB and LTBI, we used the NHP model of pulmonary TB. We randomly selected
six TB-naive RMs, six with asymptomatic LTBI after 9 to 12 weeks of exposure to a low
dose of M. tuberculosis, and an equal number that developed active TB after exposure
to a high dose of M. tuberculosis, as shown by serum C-reactive protein (CRP) (Fig. 1A),
chest X-ray (CXR) score (Fig. 1B), lung M. tuberculosis burden (Fig. 1C), and pathology
(Fig. 1D). Across different groups, RMs displayed signiﬁcant changes in the distribution
of neutrophils (Fig. 1E and H) and PMN-MDSCs (Fig. 1F and I) in both BAL ﬂuid and
peripheral blood, respectively. These results correlated directly with lung levels of
M. tuberculosis at the endpoint, disease severity, and biochemistry and blood proﬁle
representative of ATB and LTBI (see Fig. S2 in the supplemental material). While no
signiﬁcant differences in M-MDSC abundance were observed in BAL ﬂuid (Fig. 1G) and
peripheral blood (Fig. 1J), a subset of NHPs recorded higher M-MDSC fractions in
peripheral blood of ATB animals (Fig. 1J).
Abundance of MDSCs among the three study groups—ATB, LTBI, and naive
RMs. To further understand the localization of MDSCs at the primary site of infection
(i.e., the lungs), we stained formalin-ﬁxed and parafﬁn-embedded lung sections
from naive, LTBI, and ATB animals with markers speciﬁc for MDSCs, as well as other
functional markers, and analyzed the results using confocal microscopy. The sections were stained for PMNs as well as M-MDSCs using multilabel ﬂuorescence
immunohistochemistry. PMN-MDSCs were identiﬁed as the granulocytes coexpressing CD66abce (a marker for PMNs in RM and in humans) and CD33 (characteristic
surface marker for MDSCs). Furthermore, PMN-MDSCs (CD66abce1 CD331) were
stained for several other markers that correlate with the immunosuppressive nature
of MDSCs. M-MDSCs were identiﬁed as mononuclear cells expressing CD14 but not
HLA-DR (CD141 HLA-DR2). Macaques form human-like granulomas during M. tuberculosis infection (46), which are highly organized and structured with variable cellular composition across different layers (Fig. 1K). The core is usually comprised of
caseum rich in neutrophils, surrounded by a layer of myeloid cells—mainly macrophages and giant cells—which are surrounded by a lymphocyte-rich cuff at the periphery of the granuloma (Fig. 1K). We assessed differences in MDSC abundance in
the lungs of ATB, LTBI, and naive NHPs and also assessed the spatial localization
of MDSCs in different layers of granuloma. We observed an increase in frequencies
of lung neutrophils and PMN-MDSC populations that correlated with the severity of
disease (Fig. 2A to F). Furthermore, PMN-MDSCs from animals with active TB demonstrated a higher immunosuppressive potential, as indicated by higher expression of
IDO1 (Fig. 2A to G). The core of the granuloma was comprised of mainly neutrophils

FIG 3 Legend (Continued)
sections depicting proliferating PMN-MDSCs in control naive lung (A) and granuloma obtained from LTBI (B) and RMs with ATB (C). (D) Multilabel
immunohistochemistry images exhibiting the distribution of proliferating PMN-MDSCs stained with CD66abce (green), CD33 (red), Ki67 (magenta),
and DAPI (blue) in naive, LTBI, and ATB lung sections. (E) Graphical representation depicting a comparison of estimated fractions of Ki671 PMNMDSCs among the three groups. (F) Confocal images showing the distribution of proliferating PMN-MDSCs in various regions of a granuloma in
ATB lung. (G) Estimated fraction of proliferating PMN-MDSCs (CD66abce1 CD331 Ki671) in the necrotic core (NC), intermediate myeloid layer (IM),
lymphocytic cuff (LC), active lung interstitium (ALI), and naive lung interstitium (NLI). Statistical signiﬁcance by one-way ANOVA with Tukey’s
multiple-testing correction: *, P , 0.05; ****, P , 0.0001. Data represent mean 6 SEM (n = 4).
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lomatous TB niche and consequently the potential for reactivation from latent TB
to ATB.

FIG 4 PMN-MDSCs recruited to the lungs of M. tuberculosis-infected macaques express immunomodulatory cytokines and matrix
metallopeptidase. (A) Confocal images depicting the expression of immunomodulatory molecule IL-10 by PMN-MDSCs in lungs of naive, LTBI,

(Continued on next page)
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DISCUSSION
Localization of MDSCs to malignant tissues is accompanied by an increase in their
frequencies in the peripheral circulation. MDSCs from both intratumoral regions and
peripheral circulation induce similar immunosuppressive capabilities, and their recruitment has been suggestive of severity and progression of cancer as well as treatment
failure (22, 55). A number of studies have established a similar increase in MDSC frequencies associated with ATB in murine models (10, 36) and human patients (7–9, 30,
33, 41). These studies also observed similar phenotypes and functions of MDSCs in murine (10, 36) and human (7–9, 30, 33, 41) ATB. Furthermore, MDSCs obtained from peripheral blood mononuclear cells (PBMCs), BAL ﬂuid, and pleural effusions of ATB
patients also demonstrated similar immunosuppressive capabilities, with a positive
correlation with progression and inverse correlation with treatment success (7–9, 30,
33, 41). However, studies to interrogate phenotypic, functional, and localization
aspects of MDSCs in the TB granulomas remain scarce, due to the challenges associated with sampling granulomas from human lungs and the inability of most murine
models to mimic human-like granulomas.

FIG 4 Legend (Continued)
and ATB lung sections. (B and C) Graphs showing the fractions of IL-101 PMNs (CD66abce1 IL-101) (B) and IL-101 PMN-MDSCs (CD66abce1
CD331 IL-101) (C) in naive, LTBI, and ATB groups. (D) Images showing the differential distribution of IL-101 PMN-MDSCs in different
granuloma regions. (E and F) Estimated fractions of IL-101 PMNs (CD66abce1 IL-101) (E) and IL-101 PMN-MDSCs (CD66abce1 CD331 IL-101)
(F) in the necrotic core (NC), intermediate myeloid layer (IM), lymphocytic cuff (LC), active lung interstitium (ALI), and naive lung interstitium
(NLI). (G) Multilabel confocal images of PMN-MDSCs expressing MMP-9 in naive, LTBI, and ATB lung sections. (H and I) Graphical
representation of fractions of PMNs expressing MMP-9 (CD66abce1 MMP-91) (H) and PMN-MDSCs expressing MMP-9 (CD66abce1 CD331
MMP-91) (I). (J) Images showing distribution of MMP-91 PMN-MDSCs in different layers of TB granuloma. (K and L) Graphs depicting the
spatial distribution of MMP-91 PMNs (CD66abce1 MMP-91) (K) and MMP-91 PMN-MDSCs (CD66abce1 CD331 MMP-91) (L). Statistical
signiﬁcance by one-way ANOVA with Tukey’s multiple-testing correction: *, P , 0.05; **, P , 0.01; ***, P , 0.001; ****, P , 0.0001. Data
represent mean 6 SEM (n = 4).
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and was almost completely devoid of PMN-MDSCs (Fig. 2H to J). The intermediate
zone of granuloma is comprised mostly of myeloid cells and is demarcated by high
IDO1 expression. PMN-MDSCs were only very sparsely present in this zone (Fig. 2H
to J). PMN-MDSCs were also scarce in the interstitial lung tissue of ATB animals
(Fig. 2J). Throughout all lung sections, PMN-MDSCs were almost completely localized to the lymphocytic cuff at the periphery of the granuloma (Fig. 2H to J). PMNMDSCs localizing to the lymphocytic cuff also had a higher expression of IDO1
(Fig. 2H and K).
Expression of immunosuppressive effectors/mediators on RM MDSCs. During
ATB, not only were MDSCs recruited to the lungs of RMs in greater numbers and
localized to the lymphocytic cuff of granuloma, but they also exhibited higher Ki67
expression (Fig. 3A to G). This result suggests either a higher proliferative potential
in MDSCs in situ or their recent arrival from the periphery (or both). RMs with ATB
also harbored MDSCs with signiﬁcantly higher expression of IL-10 (Fig. 4A to F),
MMP-9 (Fig. 4G to L), iNOS (Fig. 5A to D), and PD-L1 (Fig. 6A to D). Expression of
these markers of T cell dysfunction was highest in MDSCs located in the lymphocytic
cuffs. We did not, however, observe any signiﬁcant differences in arginase expression across groups or layers of granuloma (Fig. 5E to H), indicating that arginase is
neither constitutively expressed nor a crucial immunosuppressive mediator for
MDSC-driven immune dysfunction in the lungs of ATB macaques. Functional studies
in murine tumor models have also reported and validated that arginase is not inherently expressed in MDSCs and is not required by MDSCs for eliciting an immunosuppressive function (54).
Although comparatively infrequent relative to PMN-MDSCs, the M-MDSC population in the lung followed the same trend in localization, with higher proportions being
recruited in lungs of ATB animals (Fig. 6E to J) and localizing to the lymphocytic cuffs
of granuloma (Fig. 6K to M).

FIG 5 PMN-MDSCs in the lungs of M. tuberculosis-infected macaques express iNOS but not arginase. (A and E) Multilabel confocal
images exhibiting the expression of iNOS (A) and arginase (E) by PMN-MDSCs in sections of naive, LTBI, and ATB lungs. (B and F)
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We used the RM model of TB to overcome this knowledge gap and characterize
MDSCs associated with lung TB granulomas. As expected, higher frequencies of MDSCs
in blood and BAL ﬂuid were associated with ATB compared to LTBI or baseline.
Increased localization of PMN-MDSCs to the lungs of RMs with ATB was speciﬁcally
observed. MDSC accumulation in lung parenchyma associated with progression of TB
has been reported in murine models (45, 56). M. tuberculosis infection in necrosis-prone
NOS22/2 mice has attributed MDSC localization to the edges of necrotic granulomas
(9, 56). NHPs in the ATB group also recorded a similar absence of MDSCs in the internal
core or myeloid layers of granuloma. MDSCs speciﬁcally localized to the outer lymphocytic cuffs at the periphery of TB granulomas of ATB macaques. TB granulomas are
known to have dysfunctional T cell responses and restricted T cell access (57–60).
While this phenomenon was broadly believed to be induced by MDSCs, our ﬁndings
support the premise that MDSCs in the NHP TB model restrict T cells and suppress their
effector functions at the periphery of the granulomas. Despite PMNs being the abundant population in the granuloma core and macrophages primarily constituting the intermediate myeloid layer, MDSCs demonstrated a preferred localization to the lymphocytic cuff. Another trait of these MDSCs was higher Ki67 expression, which is indicative
of recent differentiation from a proliferating precursor. The PMN populations from the
core exhibit a lack of Ki67 expression indicative of longer survival time, possibly
because of M. tuberculosis-induced inhibition of constitutive apoptotic pathways leading to delayed cell death (61, 62).
Proliferative signatures in MDSCs suggest their rapid turnover at this crucial
immune synapse—the periphery of the granuloma. Furthermore, our results suggest downstream dysfunctional T cell responses against M. tuberculosis in animals
with increased MDSC recruitment. Due to their unique localization to the lymphocytic cuff of the granuloma, PMN-MDSCs are important immunocytes regulating
granuloma dynamics, and our results at least partially explain the restriction of T
cell access and dysfunctional anti-TB activity in the active granuloma. The ﬁndings
in this study suggest that adjunctive therapeutics targeting MDSCs could be a
potential strategy for improving treatment outcome by helping to resolve the granuloma and consequently hasten clearance of M. tuberculosis within this unique
environment.
Inﬂammation and inﬂammatory chemokines efﬁciently drive MDSC growth and
recruitment. TB-induced inﬂammatory responses may drive the localized recruitment
and systemic proliferation, as has been observed in cancer. MDSC-driven immunosuppression can also promote TB growth and trigger dysfunctional adaptive responses.
While both of these effects appear to be convergent, our current data are based on the
distinct modeling of different disease conditions (i.e., LTBI versus ATB versus naive
macaques) and cannot quantify the in vivo immune scenario in a fully accurately manner. The comprehensive spatial analysis of granulomatous and nongranulomatous
lung sections from naive, LTBI, and ATB animals helps clarify the role of MDSCs in
potentially driving immunological dysfunction at the host-pathogen interface in granulomas by restricting T cell access to internal layers of the granuloma and by suppressing T cell function at the periphery. Further, interrogation of the underlying mechanisms needs an entirely new set of experiments involving functional blockade of
MDSCs and/or MDSC mediators.

FIG 5 Legend (Continued)
Graphical representation of the fractions of PMN-MDSCs expressing iNOS (CD66abce1 CD331 iNOS1) (B) and arginase (CD66abce1
CD331 Arg1) (F) in naive, LTBI, and ATB groups. Shown are the images depicting the distribution of iNOS1 PMN-MDSCs (C) and
arginase1 PMN-MDSCs (G) in various layers of granuloma. (D and H) Estimated fractions revealing the distribution of PMN-MDSCs
expressing iNOS (CD66abce1 CD331 iNOS1) (D) and PMN-MDSCs expressing arginase (CD66abce1 CD331 Arg1) (H) in the necrotic core
(NC), intermediate myeloid layer (IM), lymphocytic cuff (LC), active lung interstitium (ALI), and naive lung interstitium (NLI). Statistical
signiﬁcance by one-way ANOVA with Tukey’s multiple-testing correction: *, P , 0.05; **, P , 0.01; ***, P , 0.001; ****, P , 0.0001. Data
represent mean 6 SEM (n = 4).
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FIG 6 PMN-MDSCs in the lungs of M. tuberculosis-infected macaques express higher PD-L1. (A and C) Multilabel immunohistochemistry images
depicting the expression of programmed cell death ligand-1 (PD-L1) by MDSCs in naive, LTBI, and ATB lung sections (A) and different regions of
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Animals, infection, and treatment. We randomly selected 6 TB-naive RMs and 6 RMs infected with
a low dose of M. tuberculosis CDC1551 via aerosol, which maintained LTBI for 9 weeks postinfection, and
6 RMs infected with a high dose of M. tuberculosis CDC1551, again via aerosol, which developed ATB
characterized by pyrexia, rapid weight loss, elevated serum CRP levels, high CXR scores, and detection of
viable M. tuberculosis CFU in the BAL ﬂuid and lungs. Two of the seven animals in the active TB group
were female. However, female animals were not included in the other groups. The three groups of NHPs
belong to different cohorts, but the NHPs with latent and active TB were from the same group of macaques infected with low and high doses of M. tuberculosis, respectively. Low-dose M. tuberculosis infection
involved depositing 5 to 10 CFU of the M. tuberculosis CDC1551 strain into the lungs of RMs, while highdose infection deposited 50 to 100 CFU of M. tuberculosis CDC1551. The animals were subjected to
weekly physical examinations by veterinarians, including body temperature and weight, and complete
blood chemistries, including CRP, were evaluated.
Measurement of M. tuberculosis infection progression and TB disease. To measure the extent of
TB disease following aerosol M. tuberculosis infection in the various groups of animals, we studied serum
CRP levels weekly, along with CXR and viable M. tuberculosis CFU recorded in lungs at necropsy, as
described earlier (59, 63–68).
Flow cytometry. Flow cytometry was performed on whole blood and lung samples from all animals,
as previously described (59, 63–68). At necropsy, PBMCs and lung cells were isolated from each animal
for ﬂow cytometric analysis to characterize MDSCs. Antibodies used for analysis of MDSC populations
included the following: from BD Biosciences, CD3 (clone SP34-2), CD4 (clone L200), CD8 (clone RPA-T8),
CD20 (clone 2H7), HLA-DR (clone L243), anti-CD11b (ICRF44), anti-CD14 (M5E5), and Ki67 (clone B56),
and from Miltenyi Biotec (Auburn, CA), anti-CD33 (clone AC104.3E3) and anti-CD66abce (TET2) (59, 63).
Confocal microscopy. Multilabel ﬂuorescence immunohistochemistry was performed on formalin-ﬁxed, parafﬁn-embedded tissue as described previously (69, 70). Brieﬂy, formalin-ﬁxed lung sections were cut into 5-m m-thick sections. Slides were deparafﬁnized in xylenes and underwent rehydration with subsequent gradations of ethanol and distilled water (dH2O). Heat-induced antigen
retrieval (HIER) was performed using citrate buffer (10 mM [pH 6]) at 95 to 100°C for 20 min, followed
by blocking in 3% bovine serum albumin (BSA)–Tris-buffered saline with Tween 20 (TBST).
Subsequently, the slides were incubated with the respective primary antibodies for 2 h followed by
subsequent incubation with the ﬂuorophore-conjugated secondary antibody for 45 min at room temperature (RT). Slides were stained with DAPI (49,6-diamidino-2-phenlyindole) and visualized using a
Zeiss LSM 800 confocal microscope. Fifteen ﬁelds/animal/group were captured, and quantiﬁcation
was done using Image J software.
Statistical analyses. Statistical comparisons were performed using two-tailed unpaired t tests for
comparisons involving two groups, whereas, one-way analysis of variance (ANOVA) in GraphPad Prism
with Tukey’s correction for multiple comparisons was used whenever data sets involved more than two
groups.
Study approval. All animal procedures and work were speciﬁcally approved by the Texas
Biomedical Research Institute and Tulane National Primate Research Center Institutional Animal Care
and Use Committees. All work related to biological containment was approved by the Texas Biomedical
Research Institute and the Tulane Institutional Biosafety Committees.
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FIG 6 Legend (Continued)
granuloma (C). (B and D) Graphical representation of the fractions of PD-L11 PMN-MDSCs (CD66abce1 CD331 PD-L11) in naive, LTBI, and ATB
groups (B), as well as in the necrotic core (NC), intermediate myeloid layer (IM), lymphocytic cuff (LC), active lung interstitium (ALI), and naive lung
interstitium (NLI) (D). (E to G) Tiled confocal images (4-by-4 ﬁelds at 10 magniﬁcation) from lung sections of naive (E), LTBI (F), and ATB (G) lung
sections stained with CD14 (green) and HLA-DR (red), depicting the distribution of monocytic-myeloid-derived suppressor cells (M-MDSCs)
represented by CD141 HLA-DR2. (H to J) Estimated fractions of monocytes (CD141) (H), M-MDSCs (CD141 HLA-DR2) (I), and immunosuppressive
monocytes (CD141 HLA-DR1) (J) in naive, latent, and ATB groups. (K to M) Spatial distribution of monocytes (CD141) (K), M-MDSCs (CD141 HLADR2) (L), and immunosuppressive monocytes (CD141 HLA-DR1) (M) in the NC, IM, LC, ALI, and NLI. Statistical signiﬁcance by one-way ANOVA with
Tukey’s multiple-testing correction: *, P , 0.05; **, P , 0.01; ***, P , 0.001; ****, P , 0.0001. Data represent mean 6 SEM (n = 4).
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